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Summary
Background Childhood pneumonia causes substantial mortality and morbidity. Accurate measurements of pneumonia 
incidence are scarce in low-income and middle-income countries, particularly after implementation of pneumococcal 
conjugate vaccine. We aimed to assess the incidence, severity, and risk factors for pneumonia in the ﬁ rst year of life 
in children enrolled in a South African birth cohort.
Methods This birth cohort study is being done at two sites in Paarl, a periurban area of South Africa. We enrolled 
pregnant women (>18 years) and followed up mother–infant pairs to 1 year of age. We obtained data for risk factors 
and respiratory symptoms. Children received 13-valent pneumococcal conjugate vaccine according to national 
immunisation schedules. We established pneumonia surveillance systems and documented episodes of ambulatory 
pneumonia and pneumonia warranting hospital admission. We calculated incidence rate ratios for pneumonia with 
mixed-eﬀ ects Poisson regression.
Findings Between May 29, 2012 and May 31, 2014, we enrolled 697 infants who accrued 513 child-years of follow-up. 
We recorded 141 pneumonia episodes, with an incidence of 0·27 episodes per child-year (95% CI 0·23–0·32). 32 
(23%) pneumonia cases were severe pneumonia, with an incidence of 0·06 episodes per child-year (95% CI 
0·04–0·08). Two (1%) of 141 pneumonia episodes led to death from pneumonia. Maternal HIV, maternal smoking, 
male sex, and malnutrition were associated with an increased incidence of pneumonia.
Interpretation Pneumonia incidence was high in the ﬁ rst year of life, despite a strong immunisation programme 
including 13-valent pneumococcal conjugate vaccine. Incidence was associated with pneumonia risk factors that are 
amenable to interventions. Prevention of childhood pneumonia through public health interventions to address these 
risk factors should be strengthened.
Funding Bill & Melinda Gates Foundation, South African Thoracic Society, Federation of Infectious Diseases Societies 
of South Africa, and University of Cape Town.
Copyright © le Roux et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Pneumonia is the leading cause of death in children, 
accounting for about 17% of 6·3 million child deaths in 
2010—more than HIV, measles, and malaria combined.1,2 
Pneumonia also contributes substantially to health-care 
use in childhood, with an estimated 120 million episodes 
annually.3 The burden of pneumonia is disproportionately 
high in African children, with 36 million pneumonia 
cases and 600 000 pneumonia-associated deaths annually.3 
Chronic respiratory complications such as bronchiectasis 
frequently arise after childhood pneumonia, in up to 13% 
of children admitted to hospital.4 As such, understanding 
of the incidence and severity of pneumonia is important 
to identify preventive interventions, plan health systems, 
and make projections of burden of disease.
Longitudinal community-based studies with reliable 
measurements of pneumonia incidence are rare in low-
income and middle-income countries.5 Estimates of 
pneumonia incidence have therefore been modelled on 
the basis of previous incidence and risk-factor prevalence. 
The most recent global estimate of pneumonia incidence 
in children younger than 5 years from low-income and 
middle-income countries was 0·22 episodes per child-
year, with 11·5% of cases meeting criteria for severe 
disease. The country-speciﬁ c estimate for South Africa 
was 0·14 episodes per child-year, with 11·1% of cases 
deﬁ ned as severe.6
Randomised controlled trials of pneumococcal 
conjugate vaccination, using 7-valent or 9-valent vaccine, 
reported substantial decreases in the incidence of clinical 
or radiologically conﬁ rmed pneumonia, and hospital 
admissions for pneumonia.7–11 After introduction of the 
7-valent vaccine, then the 10-valent and 13-valent vaccines, 
into national immunisation programmes, substantial 
reductions in the incidence and severity of childhood 
pneumonia were reported in high-income countries,12–15 
and in Uruguay16 and Brazil.17 However, data for sub-
Saharan Africa are scarce, despite the continent’s 
substantial burden of childhood pneumonia and high 
incidence of severe disease.
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The South African Expanded Program On 
Immunisation recommends four doses of a ﬁ ve-vaccine 
combination (diphtheria, tetanus, acellular pertussis, 
Haemophilus inﬂ uenzae type b, and inactivated polio 
vaccine) given at the ages of 6, 10, and 14 weeks, and 
18 months, and measles vaccine at 9 and 18 months of 
age. 7-valent pneumococcal vaccination was introduced in 
April, 2009, with a novel schedule (6 weeks, 14 weeks, and 
9 months, with no catch-up doses given); this vaccine was 
replaced with the 13-valent formulation in June, 2011.18 
From February to May, 2012, children aged 18–35 months 
received a catch-up dose of the 13-valent vaccine.
The Drakenstein Child Health Study is investigating 
the incidence and long-term consequences of childhood 
pneumonia in a South African birth cohort. We examined 
the incidence and severity of early-life pneumonia in 
this setting, and associations involving established 
sociodemographic, clinical, and behavioural risk factors 
for childhood pneumonia.
Methods
Study design and participants
This birth cohort study being done at two sites in Paarl, a 
periurban area 60 km outside Cape Town, South Africa.19 
Study sites were in two clinics (TC Newman and 
Mbekweni) roughly 5 km apart and serving two separate 
communities with a combined population of about 
200 000 people. Residents of both areas have low 
socioeconomic status, but are ethnically, linguistically, 
and culturally heterogeneous. The TC Newman clinic 
serves a population composed of mostly Afrikaans-
speaking, mixed-race individuals; the Mbekweni clinic’s 
population is mainly isiXhosa-speaking black Africans.19
We enrolled pregnant women who were between 20 and 
28 weeks’ gestation and attending antenatal care at one of 
the two clinics; we followed up women through pregnancy 
and childbirth. Exclusion criteria were age younger than 
18 years and intention to leave the area within 1 year.
Ethics approval was obtained from the University of 
Cape Town Faculty of Health Sciences Human Research 
Ethics Committee (Human Research Ethics committee 
reference numbers 401/2009 and 651/2013) and the 
Provincial Child Health Research committee. Mothers 
provided written informed consent at enrolment.
Procedures
Questionnaires about maternal health were administered 
and we obtained antenatal data. Obstetric care was 
provided at Paarl Hospital where all births took place. 
Detailed birth information was obtained at the time of 
delivery. Infant follow-up visits were at 6, 10, and 14 weeks 
old, and 6, 9, and 12 months old.19 Trained study nurses 
did interviews in the mother’s home language. Data for 
environmental exposures, pneumonia risk factors, 
anthropometry, and the child’s respiratory symptoms 
were obtained at scheduled visits. Missed visits were 
rebooked with a study mobile phone network system or 
by study community-based ﬁ eldworkers.
Mothers were counselled about respiratory symptoms at 
every visit and advised to attend the study site or contact 
study staﬀ  whenever the child developed cough or 
TC Newman clinic 
(n=359)
 Mbekweni clinic 
(n=338)
Maternal characteristics
Race and ethnic origin
Black African 5 (1%) 337 (99%)
Mixed race 354 (99%) 1 (<1%)
In formal employment 109 (30%) 69 (20%)
Receives national child support grant 200 (56%) 188 (56%)
Lives in formal housing 266 (74%) 182 (54%)
Household crowding
Three or fewer people 79 (22%) 145 (43%)
Four or ﬁ ve people 138 (39%) 106 (31%)
More than ﬁ ve people 141 (39%) 86 (26%)
Missing data 1 (<1%) 1 (<1%)
Education
Primary school only 25 (7%) 35 (10%)
Some secondary school 179 (50%) 182 (54%)
Finished secondary school 155 (43%) 120 (36%)
Missing data 0 1 (<1%)
Socioeconomic status quartile
Lowest 52 (14%) 107 (32%)
Moderately low 96 (27%) 106 (31%)
Moderately high 88 (25%) 73 (22%)
Highest 123 (34%) 51 (15%)
Missing data 0 1 (<1%)
HIV infected 9 (2%) 121 (36%)
Self-reported smoker 162 (45%) 14 (4%)
Infant characteristics
Sex
Male 206 (57%) 166 (49%)
Female 153 (43%) 172 (51%)
Preterm (<37 weeks) 52 (15%) 44 (13%)
Low birthweight (<2500 g) 70 (20%) 38 (11%)
Birthweight (kg) 2·99 (2·59–3·40) 3·12 (2·77–3·45)
Z score
Weight-for-age –0·45 (–1·33 to 0·25) –0·30 (–1·0 to 0·43)
Height-for-age –0·68 (–1·67 to 0·1) –0·18 (–1·26 to 0·59)
Feeding choice
Never breastfed 31 (9%) 105 (31%)
Exclusively breastfed for 6 months* 21/231 (9%) 27/216 (13%)
Mixed feeding at 6 months* 139/231 (60%) 66/216 (31%)
Exclusive formula feeding at 6 months* 71/231 (31%) 123/216 (57%)
Age at censoring (days) 358 (186–365) 308 (166–365)
Vaccination coverage
All primary series doses given on time 196/329 (60%) 206/308 (67%)
All primary series doses given, some doses late 54/329 (16%) 73/308 (24%)
At least one primary series dose missed 79/329 (24%) 29/308 (9%)
Data are n (%), median (IQR), or n/N (%). *Data for participants with completed 6-month feeding questionnaires.
Table 1: Baseline characteristics
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diﬃ  culty breathing, in addition to scheduled study visits. 
Study nurses were trained to diagnose pneumonia or 
severe pneumonia according to WHO clinical case 
deﬁ nitions.20 Pneumonia was diagnosed in children with 
cough or diﬃ  culty breathing and age-speciﬁ c tachypnoea 
(≥50 breaths per min for children aged 2–12 months) or if 
the child had lower chest wall indrawing. Severe 
pneumonia was diagnosed in children younger than 
2 months with tachypnoea (>60 breaths per min) or lower 
chest wall indrawing, or in children of any age if the child 
had a general danger sign (ie, cyanosed, unable to drink, 
seizures, or decreased level of consciousness).20 The 
treating doctor made the decision to admit a child to 
hospital; indications included severe pneumonia, hypoxia 
(oxygen saturation of ≤92% in room air), or poor social 
circumstances in which ambulatory treatment was not 
feasible. Events that happened more than 14 days after 
admission or a previous event were considered to be new-
onset, community-acquired pneumonia.
An active surveillance system was established to detect 
participants with pneumonia or severe pneumonia. Study 
staﬀ  undertook pneumonia surveillance at primary care 
clinics and at Paarl Hospital on weekdays during working 
hours (0800–1600 h); surveillance continued at Paarl 
Hospital after hours and over weekends when clinics were 
closed. If a participant attended a primary health-care 
clinic or the emergency unit at Paarl Hospital, the health-
care provider could contact the study nurse on the 24 h 
mobile phone number. Mothers were given the mobile 
phone number to enable them to contact the study nurse 
on call if their child became ill. The study doctor provided 
regular training for all primary health-care nurses in the 
accurate assessment of symptoms and signs in young 
children, and to ensure birth cohort participants were 
referred to the research study site when pneumonia or 
severe pneumonia was diagnosed.
Statistical analysis 
The overall sample size for the study was 1000 mother–
infant pairs to provide at least 550 pneumonia 
episodes; this preliminary analysis was completed after 
500 child-years of follow-up had been accrued to assess 
pneumonia incidence with precision of plus or minus 
0·05 cases per child-year. On the basis of vaccine studies, 
we expected the incidence of clinically deﬁ ned 
pneumonia or severe pneumonia to be roughly 10% 
lower in this vaccinated cohort than pneumonia 
incidence estimates reported before the introduction of 
pneumococcal conjugate vaccine. We also expected 
signiﬁ cant associations of pneumonia with maternal 
smoking status, household crowding, low birthweight, 
and suboptimum breastfeeding.
For exploratory data analysis, we summarised continuous 
variables as medians with IQRs and categorical variables 
as percentages with 95% CIs. We compared medians with 
rank-sum tests and proportions with χ² tests. We derived 
Z scores from WHO child growth standards21 at birth and 
at every follow-up visit; we used the median of all the 
weight-for-age Z scores for each child to summarise 
nutrition status over the duration of follow-up. Children 
were considered severely underweight or stunted if weight-
for-age and length-for-age Z scores were less than –2. 
Follow-up was censored at last visit seen, death, or 1 year of 
age. We divided observation of each child into 1 month 
intervals, with 6299 intervals clustered around 697 infants. 
We analysed factors associated with pneumonia events for 
the whole cohort and by study site. For multivariable 
modelling of pneumonia incidence we used mixed-eﬀ ect 
Poisson models, including a random intercept for each 
infant; results are presented as incidence rate ratios with 
95% CIs. Because weight-for-age Z scores are likely to be a 
causal intermediate through which diﬀ erent risk factors 
aﬀ ect pneumonia risk, we developed separate models to 
include weight-for-age Z score. In comparisons of seasonal 
incidence we categorised December to February as 
summer, March to May as autumn, June to August as 
winter, and September to November as spring. We did 
analyses with Stata (version 11).
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between May 29, 2012 and May 31, 2014, we enrolled 
697 infants who accrued 513 child-years of follow up 
(appendix). In the ﬁ rst year of life, 13 (2%) infants died, 
Figure 1: Coverage of routine childhood vaccinations throughout the ﬁ rst 
year of life
Haemophilus inﬂ uenzae type b conjugate vaccine at 6, 10, and 14 weeks, and 
pneumococcal conjugate vaccine at 6 weeks, 14 weeks, and 9 months.
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and 89 (13%) were disenrolled (12 mothers withdrew 
consent, 51 relocated, 17 were unable to be contacted, and 
nine disenrolled for other reasons). Of the 595 children 
still in follow-up on May 31, 2014, 309 (52%) were 1 year 
or older, and 286 (48%) were younger than 1 year. Most 
children who were disenrolled remained in follow-up and 
in contact with the study staﬀ  until the date of termination, 
so their health outcomes are known. We recorded 
diﬀ erences in baseline characteristics of mothers and 
infants between the two enrolment sites (table 1). 
Exposure to environmental tobacco smoke was common: 
a quarter of mothers self-reported smoking, with higher 
rates at TC Newman than Mbekweni (table 1), whereas 
439 (63%) children were reported to share a household 
with at least one cigarette smoker. Median birthweight 
and infant nutritional status were lower at TC Newman 
than Mbekweni (table 1). Roughly a ﬁ fth of mothers were 
HIV-infected, with higher prevalence at Mbekweni than 
TC Newman (table 1); no infants were HIV infected. 
Although 616 (88%) mothers started breastfeeding, only 
163 (31%) of 519 were exclusively breastfeeding by 
4 months, and 48 (11%) of 447 by 6 months (table 1).
We recorded high immunisation coverage of primary 
series vaccinations: 512 (98%) of 561 infants received a 
6-week vaccine, 521 (94%) of 552 received a 10-week 
vaccine, and 477 (89%) of 534 received a 14-week vaccine; 
however, these vaccines were delayed by more than 
2 weeks in 37 (7%), 83 (15%), and 115 (22%) infants, 
respectively (ﬁ gure 1). Coverage of 9-month vaccination 
was lower than coverage of earlier vaccinations, with 304 
(75%) of 403 children receiving a vaccination at 9 months; 
25 (6%) 9-month vaccines were given late (ﬁ gure 1).
165 episodes met the clinical case deﬁ nition of 
pneumonia. 24 (14%) episodes took place on the ﬁ rst day 
of life. In 18 (11%) babies, tachypnoea and respiratory 
distress were due to preterm delivery and were treated 
with nasal continuous positive airway pressure; nine 
(5%) infants also needed surfactant therapy. Other causes 
of respiratory distress on the ﬁ rst day of life were 
congenital pneumonia in two babies, and one congenital 
diaphragmatic hernia. With exclusion of the 24 events 
that arose on the ﬁ rst day of life, we recorded 141 episodes 
of community-acquired pneumonia during the ﬁ rst year 
(table 2), an incidence of 0·27 episodes per child-year 
(95% CI 0·23–0·32). These 141 episodes were in 
109 children; 22 children had two episodes, nine children 
had three episodes, and one child had four episodes. In 
four (3%) episodes, we noted improvement in tachypnoea 
after bronchodilator administration. We recorded seven 
cases of community-acquired pneumonia in the ﬁ rst 
month of life (table 2). Incidence of community-acquired 
pneumonia from the second month to 1 year of age was 
0·29 episodes per child-year (95% CI 0·25–0·35). 
Incidence was lowest in the ﬁ rst month, highest in the 
third month, and decreased to 0·24 episodes per child-
year in the 12th month (ﬁ gure 2). Pneumonia incidence 
in winter was four times higher than in summer (table 2).
 Pneumonia 
events 
(n=141)
Person-
time 
(years)
Incidence of 
pneumonia (95% CI; 
episodes per child-year)
Incidence rate ratio 
(95% CI)
Study site
Mbekweni 55 (39%) 245·0 0·22 (0·17–0·29) 1
TC Newman 86 (61%) 267·8 0·32 (0·26–0·40) 1·43 (1·01–2·04)
Season
Summer 14 (10%) 130·7 0·11 (0·06–0·18) 1
Autumn 39 (28%) 148·7 0·26 (0·19–0·36) 2·45 (1·30–4·88)
Winter 47 (33%) 102·5 0·45 (0·34–0·61) 4·28 (2·31–8·42)
Spring 41 (29%) 118·1 0·35 (0·25–0·47) 3·24 (1·73–6·44)
Smoking status of mother
Non-smoker 87 (62%) 378·1 0·23 (0·18–0·28) 1
Self-reported smoker 54 (38%) 133·0 0·41 (0·30–0·53) 1·76 (1·23–2·50)
Maternal education
Primary school only 27 (19%) 45·2 0·60 (0·39–0·87) 1
Some secondary 74 (53%) 266·7 0·27 (0·22–0·35) 0·46 (0·30–0·75)
Completed secondary 40 (28%) 199·9 0·20 (0·14–0·27) 0·33 (0·20–0·57)
Sex
Female 44 (31%) 245·4 0·18 (0·13–0·24) 1
Male 97 (69%) 267·4 0·36 (0·29–0·44) 2·02 (1·40–2·96)
Child’s HIV exposure
Not exposed 106 (75%) 413·8 0·26 (0·21–0·31) 1
Exposed* 35 (25%) 99·0 0·35 (0·25–0·49) 1·38 (0·91–2·03)
Child age (months)
<1 7 (5%) 58·2 0·12 (0·05–0·25) 1
1–6 106 (75%) 292·9 0·36 (0·30–0·44) 3·00 (1·41–7·67)
6–12 28 (20%) 161·7 0·17 (0·12 - 0·26) 1·44 (0·61–3·90)
Term
Full term 96 (68%) 392·53 0·24 (0·20–0·30) 1
Preterm (<37 weeks) 54 (38%) 120·28 0·37 (0·27–0·50) 1·52 (1·04–2·20)
Birthweight (g)
≥2500 110 (78%) 430·18 0·26 (0·21–0·31) 1
<2500 31 (22%) 82·62 0·38 (0·25–0·54) 1·47 (0·95–2·20)
Z score
Weight-for-age >–2 115 (82%) 466·1 0·25 (0·20–0·30) 1
Weight-for-age <–2 26 (18%) 46·7 0·55 (0·36–0·82) 2·25 (1·41–3·48)
Length-for-age >–2 104 (74%) 426·5 0·24 (0·20–0·30) 1
Length-for-age <–2 37 (26%) 86·3 0·43 (0·30–0·59) 1·76 (1·17–2·58)
Feeding
Exclusively breastfed for 
6 months
8 (6%) 44·57 0·18 (0·07–0·35) 1
Any formula milk before 
6 months
133 (94%) 468·0 0·28 (0·24–0·34) 1·58 (0·78–3·75)
Doses of pneumococcal conjugate vaccine†
Age 6–14 weeks
First dose not given 1 2·04 0·50 (0·01–2·77) 1
First dose given on time 44 86·72 0·51 (0·37–0·68) 1·04 (0·18–41·8)
Age >14 weeks
Second dose not given 7 19·82 0·35 (0·14–0·73) 1
Second and third doses 
on time
61 276·49 0·22 (0·17–0·28) 0·62 (0·29–1·62)
Data are n (%), unless otherwise indicated. *All HIV-exposed children were HIV-uninfected. †Out of a total number of 
pneumonia events of 113 (28 events occurred before age 6 weeks, which is when the ﬁ rst dose of vaccine is due).
Table 2: Incidence of pneumonia in the cohort, by maternal and infant characteristics
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32 (23%) events of community-acquired pneumonia 
met WHO criteria for severe pneumonia; the incidence of 
severe pneumonia was 0·06 episodes per child-year 
(95% CI 0·04–0·08). 26 (81%) severe episodes were in the 
ﬁ rst 2 months of life; 21 (81%) of these infants had lower 
chest wall indrawing. In this cohort of young infants, 
WHO severe pneumonia did not correlate well with 
hypoxia: ten of 32 infants who met the criteria for severe 
pneumonia had oxygen saturations of less than 92%, with 
a similar proportion in those younger than 2 months 
(eight of 26 infants) and those older than that age (two of 
six infants). Furthermore, only 13 of 23 children with 
documented hypoxia met criteria for severe pneumonia.
86 (61%) events of community-acquired pneumonia 
were managed with outpatient care and 55 (39%) events 
warranted hospital admission. Children admitted to 
hospital with pneumonia were younger than those with 
ambulatory pneumonia, had higher median respiratory 
rates, lower median oxygen saturations, and lower 
weight-for-age and height-for-age Z scores (table 3). 
Wheeze was present in 65% of pneumonia cases 
(table 3), but was less common at the time of severe 
pneumonia (14 [44%] of 32 events) than the time of 
pneumonia (78 [72%] of 109; p=0·004). Wheeze was 
present in 82 (71%) of 115 infants older than 2 months, 
compared with ten (37%) of 26 infants younger than 
2 months (p=0·001).
Median length of hospital admission was 3 days 
(IQR 2–5). We recorded two pneumonia-related deaths, 
giving a case-fatality ratio of 1·4% (95% CI 0·1–5·0) of all 
141 cases of community-acquired pneumonia or 6% 
(0·7–21) of all 32 severe cases. The ﬁ rst death was of a 
3-week-old child with pneumococcal septicaemia and 
empyema; the second was of a 6-week-old child with a 
congenital cardiac lesion who died en route to hospital. 
Both children died before their ﬁ rst pneumococcal 
conjugate vaccine; post-mortem examinations could not 
be obtained.
Preterm delivery, severe underweight, and severe 
stunting were positively associated with incidence of 
pneumonia, whereas higher maternal educational 
achievement was negatively associated with incidence 
(table 2). Few pneumonia events took place in children 
with missed or delayed vaccinations (table 2). Children 
older than 14 weeks with a delayed second dose of 
pneumococcal conjugate vaccine had an increased 
incidence of pneumonia compared with those who 
received vaccinations on time, but this association was 
not statistically signiﬁ cant (table 2).
In multivariable analysis, age, male sex, maternal HIV 
status, and self-reported smoking were the strongest risk 
factors for pneumonia (table 4). Breastfeeding duration 
was not signiﬁ cant in the adjusted model, but was 
included as a known pneumonia risk factor. When 
weight-for-age Z score was included in the model as a 
potential causal intermediate, it was strongly associated 
with pneumonia incidence, and associations involving 
other risk factors were attenuated (table 4). HIV exposure 
and young age were the strongest risk factors for severe 
pneumonia (table 4).
Figure 2: Incidence of pneumonia during the ﬁ rst year of life
Red dots show incidence. Blue line shows ﬁ tted values. Grey line shows 95% CIs.
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Age (months) 4·52 (2·79–5·87) 2·49 (1·57–6·62) 0·01
HIV exposed 19 (22%) 16 (29%) 0·35
Preterm (<37 weeks) 12 (14%) 15 (27%) 0·05
Low birthweight (<2500 g) 16 (19%) 15 (27%) 0·23
Maternal self-reported smoking 32 (37%) 22 (40 0·74
Four or more people in the house 62 (72%) 46 (83%) 0·11
Socioeconomic status quartile 0·47
Lowest 23 (27%) 19 (35%) ··
Moderately low 30 (35%) 13 (24%) ··
Moderately high 19 (22%) 15 (27%) ··
Highest 14 (16%) 8 (15%) ··
Feeding choice
Exclusively breastfed for 6 months 3 (3%) 5 (9%) 0·30
Mixed feeding 64 (74%) 36 (65%) ··
Never breastfed 19 (22%) 14 (25%) ··
Clinical features
WHO severe pneumonia 12 (14%) 20 (36%) 0·002
Weight-for-age Z score –0·2 (–1·2 to 0·55) –1·1 (–1·81 to 0·14) 0·003
Height-for-age Z score –0·69 (-2·1 to 0·54) –2·2 (–4·1 to 0·02) 0·002
Respiratory rate (breaths per min) 56 (52–62) 62 (56–68) 0·002
Lower chest wall indrawing 36 (42%) 45 (81%) <0·0001
Wheeze 58 (67%) 34 (62%) 0·49
Fever (>38°C) 17 (24%) 26 (49%) 0·004
Unable to feed 7 (8%) 12 (22%) 0·03
Oxygen saturation (lowest) 97% (94–98) 94% (90–96) 0·001
Data are median (IQR) or n (%).
Table 3: Risk factors for and clinical features of infants with ambulatory pneumonia or pneumonia 
needing hospital admission
Articles
e100 www.thelancet.com/lancetgh   Vol 3   February 2015
Discussion
This birth cohort study provides one of the ﬁ rst 
measurements of the incidence of pneumonia in infants 
after introduction of 13-valent pneumococcal conjugate 
vaccine in a low-income to middle-income setting. We 
recorded a high incidence of pneumonia during the ﬁ rst 
year of life, and a high proportion of these cases were 
severe or warranted hospital admission. This incidence 
resulted despite high immunisation coverage and a 
strong primary health-care programme with eﬀ ective 
prevention of vertical HIV transmission. The incidence 
of pneumonia in our study (0·32 episodes per child-year) 
is more than double the estimated incidence for South 
African children younger than 5 years (0·14 episodes per 
child-year) and higher than the median estimate in 
developing countries of 0·22 episodes per child-year,6 
both of which were calculated before implementation of 
pneumococcal conjugate vaccine. The higher than 
expected incidence might be due, in part, to the young 
age of the cohort, because pneumonia incidence is 
highest in the ﬁ rst year of life.22 Moreover, the incidence 
of pneumonia was highest in infants younger than 
6 months, which shows the increased vulnerability of 
young children to pneumonia and severe pneumonia. 
The incidence was also substantially higher than that 
described in the ﬁ rst year of life in high-income countries, 
which ranges from 0·006 to 0·085 episodes per child-
year.23 However, our incidence is similar to that described 
in some other low-income and middle-income settings 
in the ﬁ rst year of life, which might signify diﬀ erences in 
populations, diagnostic certainty, or risk factors for 
pneumonia.24-26
The high incidence of pneumonia took place despite 
high immunisation coverage, including 13-valent 
pneumococcal conjugate vaccine, acellular pertussis, 
Haemophilus inﬂ uenzae type b conjugate, and measles 
vaccines. Delayed vaccination can increase vulnerability 
to pneumonia because of low protective immunity.27,28 
This study was not designed to assess the eﬀ ectiveness of 
increased numbers of vaccine doses; vaccine coverage 
was high, and few pneumonia events took place in 
children with missed or delayed vaccinations. For 
optimum protection against pneumonia, completion of a 
pneumococcal vaccine series of two primary doses plus 
one booster dose is needed.29,30 In support of this ﬁ nding, 
the incidence of pneumonia was lower in children who 
had received two or three immunisations than in those 
who had received one dose. However, young age might 
be a confounding variable because children with fewer 
immunisation doses were younger than those who had 
completed a primary series.
Despite the young age of the cohort, case-fatality ratios 
for overall pneumonia cases and for severe pneumonia 
cases were lower than the global average for children 
younger than 5 years with severe pneumonia.3 This 
ﬁ nding is probably a result of high immunisation 
coverage (reducing the severity of pneumonia); good 
access to health care by birth cohort participants; and a 
strong primary health-care programme, ensuring timely 
availability of antibiotic therapy and oxygen at community 
clinics and referral to hospital when needed.
Known risk factors for pneumonia were conﬁ rmed in 
this cohort and the magnitude of their eﬀ ects was 
quantiﬁ ed in the context of a strong primary health-care 
programme. No child was HIV infected, despite a high 
prevalence of HIV infection in pregnant women, 
showing the strong eﬀ ect of prevention of mother-to-
child-transmission programmes. However, exposure to 
HIV was a signiﬁ cant independent risk factor for 
pneumonia, especially for severe pneumonia, even after 
adjustment for feeding choice. This ﬁ nding could be due 
to developmental abnormalities of the innate31 or 
adaptive32 immune systems, limited protection due to 
compromised maternal antibodies, or increased exposure 
to infectious diseases from living in a household with a 
member who is HIV infected. This ﬁ nding draws 
attention to a group of children who, although maybe not 
HIV infected, might be especially vulnerable to the 
development of severe disease. Boys had a higher 
incidence of pneumonia than girls, possibly because of 
diﬀ erences in intrinsic immune or inﬂ ammatory 
responses,33,34 or diﬀ erences in lung structure or 
function.35 Maternal smoking was associated with 
increased pneumonia incidence; possible mechanisms 
include in-utero eﬀ ects of maternal smoking, which 
reduces infants’ lung growth,36 or postnatal exposure to 
tobacco smoke predisposing to respiratory infection or 
development of wheezing illness.37 Higher maternal 
education was signiﬁ cantly associated with decreased 
incidence of pneumonia, suggesting that maternal 
education can have a direct eﬀ ect on child health.
Exclusive breastfeeding for 6 months is recommended 
for the reduction of pneumonia incidence and mortality 
in low-income and middle-income settings.38 Similar to 
ﬁ ndings from a study in sub-Saharan Africa,39 a low 
proportion of participants sustained exclusive 
breastfeeding for 6 months. The incidence rate ratio from 
Severe pneumonia Pneumonia All pneumonia 
events (model A)
All pneumonia 
events (model B)
Male sex 1·20 (0·55–2·62) 2·49 (1·52–4·08) 2·07 (1·37–3·11) 1·98 (1·32–2·99)
HIV exposed 4·04 (1·51–10·80) 1·55 (0·81–2·96) 1·62 (1·01–2·61) 1·52 (0·98–2·36)
Maternal smoking 0·71 (0·28–1·79) 2·36 (1·45–3·82) 1·98 (1·33–2·95) 1·94 (1·32–2·83)
Any formula feeding 
before age 6 months
0·97 (0·23–4·12) 2·07 (0·70–6·17) 1·74 (0·72–4·20) 1·75 (0·73–4·14)
Child age (1 month 
units)
0·66 (0·54–0·80) 0·98 (0·92–1·03) 0·93 (0·89–0·98) 0·93 (0·88–0·98)
Weight-for-age 
Z score <–2
·· ·· ·· 1·79 (1·05–3·02)
Data are incidence rate ratio (95% CI). We adjusted all models for site of enrolment. Model A includes risk factors 
shown and Model B includes risk factors shown and weight-for-age Z score as an intermediate variable through which 
risk factors might aﬀ ect pneumonia risk.
Table 4: Incidence rate ratios for severe pneumonia, pneumonia, and total pneumonia events
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the Poisson regression suggests that suboptimum 
breastfeeding is associated with a 70% increased incidence 
of pneumonia; however, this ﬁ nding was not signiﬁ cant.
Preterm delivery and low birthweight are recognised 
risk factors for pneumonia.40 In our study, severe 
underweight and severe stunting—both markers of low 
birthweight and postnatal growth and nutrition—were 
strongly associated with increased pneumonia incidence. 
This ﬁ nding is in line with the well described association 
of malnutrition with pneumonia incidence and severity,41 
possibly due to impaired immunity or micronutrient 
deﬁ ciency. Further study of the nutritional factors 
associated with pneumonia risk in this cohort is 
underway.
Wheezing was common in children with pneumonia. 
This ﬁ nding is not unexpected because previous studies 
of children with pneumonia, including an analysis of 
more than 4000 episodes of hospital admission for lower 
respiratory tract infection in young South African 
children enrolled in a vaccine study, reported concomitant 
wheezing in about 50% of children who met WHO’s 
clinical case deﬁ nition of pneumonia.42–45 The high 
incidence of wheezing might suggest that viral infection 
(alone or with other pathogens) is the cause of pneumonia, 
or that the small airways of young children are especially 
prone to obstruction due to infection or resulting 
inﬂ ammation. Further study of the bacterial and viral 
pathogens associated with pneumonia episodes is 
underway. Because we aimed to report ﬁ ndings for all-
cause pneumonia, we included children with wheezing 
who met the WHO clinical case deﬁ nition for pneumonia. 
Moreover, existing evidence shows that viral illness, such 
as that produced by respiratory syncytial virus, constitutes 
a large global burden with a substantial case-fatality rate, 
especially in low-income and middle-income countries.46 
Although distinguishing of bronchiolitis from pneumonia 
is not possible with WHO case deﬁ nitions, this infection 
represents a range of lower respiratory tract illnesses with 
substantial morbidity and mortality.
Limitations of this study include the possibility of 
misclassiﬁ cation of pneumonia cases because of diﬀ ering 
clinical case deﬁ nitions.6 To reduce misclassiﬁ cation, we 
used standard, recently revised WHO clinical case 
deﬁ nitions to enable standardised diagnosis and 
comparison with other data and research of pneumonia 
incidence. These case deﬁ nitions were designed for 
maximum sensitivity for pneumonia diagnosis, but have 
lower speciﬁ city than other measures such as radiological 
pneumonia. A strength of this study is the consistent use 
of such case deﬁ nitions by study staﬀ . Although use of 
these standardised deﬁ nitions might lead to overdiagnosis 
of pneumonia, they are widely used globally for diagnosis 
and management, and enable comparison with data from 
other regions.
Study staﬀ  were trained and assessed in application 
of these case deﬁ nitions and strong pneumonia 
surveillance systems were established. Although study 
nurses monitored every illness episode in birth cohort 
participants, some pneumonia events could have been 
missed. The participants who were lost to follow up 
might have had pneumonia events that were not 
reported to the study team; however, because these 
participants comprised only 2% of the cohort, such 
events are unlikely to have substantially aﬀ ected the 
results. The chances that events warranting hospital 
admission were missed are low because Paarl Hospital 
is the only public hospital in the area; however, some 
ambulatory events could have been undercounted if 
mothers did not seek care. The incidence of pneumonia 
episodes might therefore represent the minimum 
incidence of pneumonia in this cohort.
These results might have low generalisability to other 
regions in Africa. However, this study was done in 
two heterogeneous communities, with meticulous 
measurement of a wide range of risk factors, allowing for 
wider generalisability to regions with similar distributions 
of risk factors. Furthermore, subgroup incidence estimates 
can be used to guide modelling of disease burden in 
regions with diﬀ erent prevalences of risk factors.
This is the ﬁ rst birth cohort study in a low-income to 
middle-income setting with a well established primary 
health-care system and an immunisation programme 
including new conjugate vaccines (panel). Prevention of 
childhood pneumonia through public health 
interventions addressing cessation of maternal smoking, 
prevention of HIV transmission, promotion of 
breastfeeding, child nutrition, and timely vaccination 
should be strengthened. To complement these ﬁ ndings, 
incidence estimations after the age of 1 year, and 
investigation of the infectious cause of childhood 
pneumonia in the context of high coverage of conjugate 
vaccination, should be prioritised for future research.
Panel: Research in context
Systematic review
We searched PubMed for articles published in English up to August, 2013, with the search 
terms “child” AND “pneumonia”. We identiﬁ ed some high quality systematic reviews of 
the incidence and global burden of childhood pneumonia. However, the published 
evidence relied mainly on modelled estimates of pneumonia incidence or extrapolation 
from child mortality statistics. Accurate longitudinal data are scarce for the incidence of 
pneumonia in children and for severity of disease, especially after introduction of 
childhood pneumococcal conjugate vaccine in low-income and middle-income countries.
Interpretation
This study is one of the ﬁ rst birth cohort studies to longitudinally investigate the 
incidence, severity, and risk factors for childhood pneumonia in a low-income to middle-
income setting after introduction of new conjugate vaccines. We noted a high incidence 
of pneumonia, with a high proportion of severe pneumonia cases in the ﬁ rst year of life. 
Exposure to environmental tobacco smoke, young age, male sex, and maternal HIV 
infection were associated with pneumonia or severe pneumonia. Childhood pneumonia 
remains an important public health problem despite the introduction of new conjugate 
vaccines. Attention to the broad determinants of childhood pneumonia is needed to 
prevent this disease burden.
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